New cancer drug enters human testing: hopes for advanced tumor treatment
NCT ID NCT06302426
Summary
This is the first human study of an experimental drug called INI-4001 for people with advanced solid tumors that have spread. The main goal is to find a safe dose and see how the body handles the drug, both by itself and when combined with other approved cancer immunotherapies. Researchers will enroll about 50 patients to carefully monitor side effects and gather early signs of whether the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cabrini Hospital
RECRUITINGMalvern, Victoria, 3144, Australia
Contact Email: •••••@•••••
Contact
-
Southern Oncology Clinical Research Unit
RECRUITINGBedford Park, South Australia, 5042, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Border Cancer Hospital
RECRUITINGAlbury, New South Wales, 2640, Australia
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.